C12N 2750/14011
Parvoviridae
C12N2750/14011 (Parvoviridae) appears on 3,127 US grants and 7,596 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,127
- Published applications
- 7,596
- Assignees
- 1,712
- Inventors
- 9,966
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 4 | 0 |
| 1994 | 4 | 0 |
| 1995 | 6 | 0 |
| 1996 | 11 | 0 |
| 1997 | 17 | 0 |
| 1998 | 31 | 0 |
| 1999 | 31 | 0 |
| 2000 | 29 | 0 |
| 2001 | 43 | 11 |
| 2002 | 40 | 76 |
| 2003 | 30 | 84 |
| 2004 | 19 | 78 |
| 2005 | 26 | 71 |
| 2006 | 37 | 65 |
| 2007 | 28 | 59 |
| 2008 | 16 | 75 |
| 2009 | 28 | 70 |
| 2010 | 42 | 68 |
| 2011 | 28 | 65 |
| 2012 | 34 | 70 |
| 2013 | 37 | 93 |
| 2014 | 48 | 125 |
| 2015 | 64 | 140 |
| 2016 | 76 | 210 |
| 2017 | 102 | 222 |
| 2018 | 118 | 304 |
| 2019 | 147 | 411 |
| 2020 | 182 | 498 |
| 2021 | 242 | 650 |
| 2022 | 240 | 759 |
| 2023 | 282 | 786 |
| 2024 | 294 | 900 |
| 2025 | 411 | 986 |
| 2026 | 361 | 720 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2750/14111DependovirusIndexing code2,862
- C12N 2750/14311ParvovirusIndexing code230
- C12N 2750/14041Use of virus, viral particle or viral elements as a vectorIndexing code59
- C12N 2750/14211ErythrovirusIndexing code36
- C12N 2750/14034Use of virus or viral component as vaccineIndexing code30
- C12N 2750/14071Demonstrated in vivo effectIndexing code22
- C12N 2750/14022New viral proteins or individual genes, new structural or functional aspects ofIndexing code14
- C12N 2750/14032Use of virus as therapeutic agent, other than vaccineIndexing code14
All 15 subgroupsShow fewer
- C12N 2750/14051Methods of production or purification of viral materialIndexing code14
- C12N 2750/14021Viruses as suchIndexing code10
- C12N 2750/14023Virus like particles [vlp]Indexing code9
- C12N 2750/14033Use of viral protein as therapeutic agent other than vaccineIndexing code7
- C12N 2750/14061Methods of inactivation or attenuationIndexing code3
- C12N 2750/14031Uses of virus other than therapeutic or vaccineIndexing code2
- C12N 2750/14088For redistributionIndexing code0
Recent patents
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
- Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment8 Oct 2026US 2026/0306667 A1Abeona Therapeutics Inc.
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
Most cited
By later US patents
- AAV transduction vectors618US 5,139,941 AUniversity of Florida Research Foundation, Inc. · 1992
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Adeno-associated virus as eukaryotic expression vector481US 4,797,368 AThe United States of America as represented by the Department of Health and Human Services · 1989